Pliant Therapeutics (PLRX) Metrics: History & Chart

Pliant Therapeutics, Inc.(PLRX)

Biotechnology · South San Francisco, CA

$1.030.00 (0.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

South San Francisco, CA

49 employees

pliantrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bernard Coulie

View full financials

Third-Party DCF Estimate (FMP)	$0.27
Price Gap vs Third-Party Estimate	-73.66%

7D Total Return	-4.63%
30D Total Return	-11.21%
YTD Total Return	-15.57%
1Y Total Return	-32.24%
3Y Total Return	-94.05%
5Y Total Return	-94.07%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-15.57%
2025	-90.74%
2024	-27.28%
2023	-6.31%
2022	+43.19%
2021	-40.58%
2020

CAGR TTM	-32.11%
CAGR 3Y	-60.95%
CAGR 5Y	-43.17%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	70.00
PE Ratio Avg TTM	47.68
PE Ratio Avg 3Y	47.68
Current VS TTM Avg	+46.80%
Current VS 3Y Avg	+46.80%
Current VS 5Y Avg	+46.80%

All Metrics

PLRX Valuation Metrics

PLRX Stock Price Metrics

PLRX Dividend Metrics

PLRX Growth Rate Metrics

PLRX Discounted Cash Flow Metrics

PLRX Returns By Period

PLRX Yearly Returns

PLRX Average Annual Returns By Period (CAGR)

PLRX Revenue Metrics

PLRX PE Ratio Metrics

PLRX PS Ratio Metrics

PLRX PB Ratio Metrics

PLRX Price to Free Cash Flow Ratio Metrics

PLRX Debt to Equity Ratio Metrics

PLRX PEG Ratio Metrics

PLRX FCF Yield

PLRX Earnings Yield

PLRX EBITDA Yield

PLRX OCF Yield

PLRX EV/EBIT Ratio Metrics

PLRX EV/EBITDA Ratio Metrics

PLRX EV/Assets Ratio Metrics

PLRX EV/Sales Ratio Metrics

PLRX Current Ratio Metrics

PLRX Quick Ratio Metrics

PLRX ROIC Metrics

PLRX Return on Assets Metrics

PLRX Return on Equity Metrics

PLRX Net Profit Margin Metrics

PLRX Gross Profit Margin Metrics

PLRX Tax Rate Metrics

PS Ratio	3043.02
PS Ratio Avg TTM	1001.33
PS Ratio Avg 3Y	113.46
Current VS TTM Avg	+203.90%
Current VS 3Y Avg	+2582.11%
Current VS 5Y Avg	+3518.69%

PB Ratio	0.43
PB Ratio Avg TTM	0.43
PB Ratio Avg 3Y	1.09
Current VS TTM Avg	-0.03%
Current VS 3Y Avg	-60.39%
Current VS 5Y Avg	-73.73%

PFCF Ratio	92.03
PFCF Ratio Avg TTM	47.92
PFCF Ratio Avg 3Y	47.92
Current VS TTM Avg	+92.07%
Current VS 3Y Avg	+92.07%
Current VS 5Y Avg	+92.07%

Debt/Equity Ratio	0.20
Debt/Equity Ratio Avg TTM	0.22
Debt/Equity Ratio Avg 3Y	0.16
Current VS TTM Avg	-11.37%
Current VS 3Y Avg	+23.25%
Current VS 5Y Avg	+72.78%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.09%
FCF Yield Avg TTM	3.20%
FCF Yield Avg 3Y	3.20%
Current VS TTM Avg	-65.94%
Current VS 3Y Avg	-65.94%
Current VS 5Y Avg	-65.94%

Earnings Yield	1.43%
Earnings Yield Avg TTM	1.90%
Earnings Yield Avg 3Y	1.90%
Current VS TTM Avg	-24.56%
Current VS 3Y Avg	-24.56%
Current VS 5Y Avg	-24.56%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	66.85
Ev/Ebit Ratio Avg TTM	31.50
Ev/Ebit Ratio Avg 3Y	31.50
Current VS TTM Avg	+112.23%
Current VS 3Y Avg	+112.23%
Current VS 5Y Avg	+112.23%

Ev/Ebitda Ratio	62.83
Ev/Ebitda Ratio Avg TTM	29.74
Ev/Ebitda Ratio Avg 3Y	29.74
Current VS TTM Avg	+111.30%
Current VS 3Y Avg	+111.30%
Current VS 5Y Avg	+111.30%

Ev/Assets Ratio	0.36
Ev/Assets Ratio Avg TTM	0.28
Ev/Assets Ratio Avg 3Y	0.84
Current VS TTM Avg	+28.19%
Current VS 3Y Avg	-57.35%
Current VS 5Y Avg	-73.55%

Ev/Sales Ratio	2802.53
Ev/Sales Ratio Avg TTM	928.39
Ev/Sales Ratio Avg 3Y	109.96
Current VS TTM Avg	+201.87%
Current VS 3Y Avg	+2448.62%
Current VS 5Y Avg	+3407.10%

Current Ratio	9.90
Current Ratio Avg TTM	13.14
Current Ratio Avg 3Y	14.22
Current VS TTM Avg	-24.69%
Current VS 3Y Avg	-30.41%
Current VS 5Y Avg	-32.83%

Quick Ratio	9.90
Quick Ratio Avg TTM	13.14
Quick Ratio Avg 3Y	14.22
Current VS TTM Avg	-24.69%
Current VS 3Y Avg	-30.41%
Current VS 5Y Avg	-32.83%

ROIC	(56.22%)
ROIC Avg 3Y	(55.55%)
ROIC Avg 5Y	(50.73%)
Current VS 3Y Avg	-1.21%
Current VS 5Y Avg	-10.82%
Current VS 10Y Avg	-40.28%

ROA	(48.60%)
ROA Avg TTM	(11.22%)
ROA Avg 3Y	(10.87%)
Current VS TTM Avg	-333.22%
Current VS 3Y Avg	-347.17%
Current VS 5Y Avg	-348.57%

ROE	(62.81%)
ROE Avg TTM	(79.09%)
ROE Avg 3Y	(60.50%)
Current VS TTM Avg	+20.58%
Current VS 3Y Avg	-3.81%
Current VS 5Y Avg	-15.73%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	+100.00%

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	-100.00%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A